{# ── Billing problem banner: payment failed (past_due) or retries exhausted (unpaid). Pro access is gated off by is_pro until the card is fixed, so prompt the user to update billing. ── #}

Red Flags Detected

  • Material Weakness (new) — Company disclosed a new material weakness in internal controls over accounting for complex financial transactions involving Greenshoe Rights under ASC 480.
NASDAQ: GTBP GT Biopharma, Inc. 10-Q

GT Biopharma doses first patient in GTB-5550 trial, but omits required controls disclosure

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade GTBP commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Feedback
View original filing on SEC.gov

Generated by AI · May 26, 2026 11:35 PM